Gongxi Qiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gongxi Qiao has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Jinwei Gao
Gannan Normal University
3 shared publications - Xia Chu
Hunan University
3 shared publications Bin Hong
State Key Laboratory of Quantitative Synthetic Biology Shenzhen Institute of Synthetic Biology Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences Shenzhen Guangdong China
2 shared publications- Daji Wang
State Key Laboratory of Quantitative Synthetic Biology Shenzhen Institute of Synthetic Biology Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences Shenzhen Guangdong China
2 shared publications - Jian-Hui Jiang
Hunan University
2 shared publications Jie Wang
State Key Laboratory of Quantitative Synthetic Biology Shenzhen Institute of Synthetic Biology Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences Shenzhen Guangdong China
2 shared publications
Latest Publications
Designing Single‐Atom Nanozymes With High Chemical Stability and Peroxidase‐Like Activity for Enhanced MRSA‐Infected Diabetic Wound Healing
Single‐atom nanozymes (SANzymes) with well‐defined electronic coordination environments can effectively mimic the catalytic activity of natural enzymes. However, low density of active sites and monoatomic instability limit their practical applications. Here, a SANzyme with both high catalytic activity and chemical stability is synthesized by integrating the advantages of noble metal porphyrins and Zr‐based metal‐organic frameworks (Zr‐MOF). Specifically, five metalloporphyrins are synthesized to compare their peroxidase‐like activity. Among them, the Ru‐porphyrin exhibiting optimal catalytic performance is axially modified with histidine (RuPH) to mimic the active site of natural peroxidase. Subsequently, RuPH is loaded onto Zr‐MOF to yield MRuPH, which possesses a high specific activity (886.2 ± 201.6 U mg – 1 ), attributable to its abundant density of active sites (6.24%) and the presence of axial histidine. Moreover, MRuPH retains its activity following exposure to 100°C, 1.0 M H 2 O 2 , or 12 months of room storage. To evaluate its application potential, MRuPH and vascular endothelial growth factor (VEGF) are co‐encapsulated into hydrogel‐based microneedles (RV@MN). The spatiotemporal coupling of MRuPH‐mediated antibacterial activity and VEGF‐induced angiogenesis promotes rapid healing of methicillin‐resistant Staphylococcus aureus ‐infected diabetic wounds. This study establishes a universal strategy for preparing high‐performance SANzymes and underscores the potential of RV@MN in treating infected wounds.
Designing Single‐Atom Nanozymes With High Chemical Stability and Peroxidase‐Like Activity for Enhanced MRSA‐Infected Diabetic Wound Healing
Single‐atom nanozymes (SANzymes) with well‐defined electronic coordination environments can effectively mimic the catalytic activity of natural enzymes. However, low density of active sites and monoatomic instability limit their practical applications. Here, a SANzyme with both high catalytic activity and chemical stability is synthesized by integrating the advantages of noble metal porphyrins and Zr‐based metal‐organic frameworks (Zr‐MOF). Specifically, five metalloporphyrins are synthesized to compare their peroxidase‐like activity. Among them, the Ru‐porphyrin exhibiting optimal catalytic performance is axially modified with histidine (RuPH) to mimic the active site of natural peroxidase. Subsequently, RuPH is loaded onto Zr‐MOF to yield MRuPH, which possesses a high specific activity (886.2 ± 201.6 U mg – 1 ), attributable to its abundant density of active sites (6.24%) and the presence of axial histidine. Moreover, MRuPH retains its activity following exposure to 100°C, 1.0 M H 2 O 2 , or 12 months of room storage. To evaluate its application potential, MRuPH and vascular endothelial growth factor (VEGF) are co‐encapsulated into hydrogel‐based microneedles (RV@MN). The spatiotemporal coupling of MRuPH‐mediated antibacterial activity and VEGF‐induced angiogenesis promotes rapid healing of methicillin‐resistant Staphylococcus aureus ‐infected diabetic wounds. This study establishes a universal strategy for preparing high‐performance SANzymes and underscores the potential of RV@MN in treating infected wounds.
Phage‐Derived Protein‐Guided Nanozymes for the Treatment of MRSA‐Infected Acute Otitis Media
Nanozymes with peroxidase‐like activity have been identified as promising nanomaterials against antimicrobial resistance. However, their in vivo efficacy is significantly limited due to the lack of bacterial targeting ability. Furthermore, the substantial accumulation of nanozymes in nontarget tissues raises concerns of potential nanotoxicity. Here, we report a single‐atom nanozyme (mFeP‑gCBD) by coupling ferriporphyrin containing monocarboxyphenyl (mFeP) and cell wall binding domain of endolysin from Staphylococcus aureus phage via a bioorthogonal reaction to achieve targeted catalytic elimination of methicillin‐resistant Staphylococcus aureus (MRSA). This nanoplatform can actively recognize MRSA in the infection microenvironment and generate high intensity of reactive oxygen species through its intrinsic peroxidase‐like activity, ultimately destroying the structure and biofilm of MRSA. Experimental results demonstrate that mFeP‑gCBD displays 20 times reduction in the effective antibacterial dose compared to untargeted mFeP. In an acute otitis media model infected with MRSA, 2 µg mL – 1 of mFeP‑gCBD significantly alleviates inflammation in the middle ear cavity and recovers mouse auditory thresholds. Remarkably, such a low applied dosage avoids dysbiosis of the commensal bacteria community and systemic toxicity. This work provides a modular design strategy for nanozymes with bacterial targeting capacity.
Phage‐Derived Protein‐Guided Nanozymes for the Treatment of MRSA‐Infected Acute Otitis Media
Nanozymes with peroxidase‐like activity have been identified as promising nanomaterials against antimicrobial resistance. However, their in vivo efficacy is significantly limited due to the lack of bacterial targeting ability. Furthermore, the substantial accumulation of nanozymes in nontarget tissues raises concerns of potential nanotoxicity. Here, we report a single‐atom nanozyme (mFeP‑gCBD) by coupling ferriporphyrin containing monocarboxyphenyl (mFeP) and cell wall binding domain of endolysin from Staphylococcus aureus phage via a bioorthogonal reaction to achieve targeted catalytic elimination of methicillin‐resistant Staphylococcus aureus (MRSA). This nanoplatform can actively recognize MRSA in the infection microenvironment and generate high intensity of reactive oxygen species through its intrinsic peroxidase‐like activity, ultimately destroying the structure and biofilm of MRSA. Experimental results demonstrate that mFeP‑gCBD displays 20 times reduction in the effective antibacterial dose compared to untargeted mFeP. In an acute otitis media model infected with MRSA, 2 µg mL – 1 of mFeP‑gCBD significantly alleviates inflammation in the middle ear cavity and recovers mouse auditory thresholds. Remarkably, such a low applied dosage avoids dysbiosis of the commensal bacteria community and systemic toxicity. This work provides a modular design strategy for nanozymes with bacterial targeting capacity.
- 1 September 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
Engineered Probiotics Secreting IL-18BP and Armed with Dual Single-Atom Catalysts for Synergistic Therapy in Ulcerative Colitis
Ulcerative Colitis (UC) involves a complex pathological process characterized by excessive reactive oxygen species (ROS) production at lesion sites and gut microbiota dysregulation. Conventional therapies are often limited by their inability to concurrently address oxidative stress, immune dysregulation, and microbial imbalance. Herein, we developed an integrated bionanoplatform (DEI) by conjugating dual single-atom catalysts (DACs) with an engineered probiotic strain, Escherichia coli Nissle 1917 (EcN). This EcN was genetically modified to stably express interleukin-18 binding protein (IL-18BP). The DACs effectively scavenge ROS in intestinal tissues via multienzyme mimetic activities, while IL-18BP neutralizes pro-inflammatory cytokines to modulate the inflammatory milieu. Orally administered, the engineered EcN delivers and retains the DACs within the intestine, significantly enhancing ROS neutralization. Concomitantly, the DACs augment colonization of the engineered EcN, thereby amplifying its therapeutic efficacy. In a dextran sulfate sodium-induced mouse colitis model, DEI effectively mitigated colitis symptoms, attenuated inflammation, and restored the abundance and diversity of the intestinal microbiota, promoting intestinal homeostasis. This multifunctional bionanoplatform thus offers a promising synergistic strategy for UC treatment by integrating ROS scavenging, immune modulation, and microbiota restoration.
- 1 September 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
Engineered Probiotics Secreting IL-18BP and Armed with Dual Single-Atom Catalysts for Synergistic Therapy in Ulcerative Colitis
Ulcerative Colitis (UC) involves a complex pathological process characterized by excessive reactive oxygen species (ROS) production at lesion sites and gut microbiota dysregulation. Conventional therapies are often limited by their inability to concurrently address oxidative stress, immune dysregulation, and microbial imbalance. Herein, we developed an integrated bionanoplatform (DEI) by conjugating dual single-atom catalysts (DACs) with an engineered probiotic strain, Escherichia coli Nissle 1917 (EcN). This EcN was genetically modified to stably express interleukin-18 binding protein (IL-18BP). The DACs effectively scavenge ROS in intestinal tissues via multienzyme mimetic activities, while IL-18BP neutralizes pro-inflammatory cytokines to modulate the inflammatory milieu. Orally administered, the engineered EcN delivers and retains the DACs within the intestine, significantly enhancing ROS neutralization. Concomitantly, the DACs augment colonization of the engineered EcN, thereby amplifying its therapeutic efficacy. In a dextran sulfate sodium-induced mouse colitis model, DEI effectively mitigated colitis symptoms, attenuated inflammation, and restored the abundance and diversity of the intestinal microbiota, promoting intestinal homeostasis. This multifunctional bionanoplatform thus offers a promising synergistic strategy for UC treatment by integrating ROS scavenging, immune modulation, and microbiota restoration.
- Open Access
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (13) , eadk7955
Surgical tumor–derived nanoplatform targets tumor-associated macrophage for personalized postsurgical cancer immunotherapy
Directly activating CD8 + T cells within the tumor through antigen-presenting cells (APCs) hold promise for tumor elimination. However, M2-like tumor-associated macrophages (TAMs), the most abundant APCs in tumors, hinder CD8 + T cell activation due to inefficient antigen cross-presentation. Here, we demonstrated a personalized nanotherapeutic platform using surgical tumor–derived galactose ligand–modified cancer cell membrane (CM)–coated cysteine protease inhibitor (E64)–loaded mesoporous silica nanoparticles for postsurgical cancer immunotherapy. The platform targeted M2-like TAMs and released E64 within lysosomes, which reshaped antigen cross-presentation and directly activated CD8 + T cells, thus suppressing B16-OVA melanoma growth. Furthermore, this platform, in combination with anti–PD-L1 antibodies, enhanced the therapeutic efficacy and substantially inhibited 4T1 tumor growth. CMs obtained from surgically resected tumors were used to construct a personalized nanotherapeutic platform, which, in synergy with immune checkpoint blockade (ICB), effectively inhibited postsurgical tumor recurrence in 4T1 tumor. Our work offered a robust, safe strategy for cancer immunotherapy and prevention of postsurgical tumor recurrence.
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (13) , eadk7955
Open AccessSurgical tumor–derived nanoplatform targets tumor-associated macrophage for personalized postsurgical cancer immunotherapy
Directly activating CD8 + T cells within the tumor through antigen-presenting cells (APCs) hold promise for tumor elimination. However, M2-like tumor-associated macrophages (TAMs), the most abundant APCs in tumors, hinder CD8 + T cell activation due to inefficient antigen cross-presentation. Here, we demonstrated a personalized nanotherapeutic platform using surgical tumor–derived galactose ligand–modified cancer cell membrane (CM)–coated cysteine protease inhibitor (E64)–loaded mesoporous silica nanoparticles for postsurgical cancer immunotherapy. The platform targeted M2-like TAMs and released E64 within lysosomes, which reshaped antigen cross-presentation and directly activated CD8 + T cells, thus suppressing B16-OVA melanoma growth. Furthermore, this platform, in combination with anti–PD-L1 antibodies, enhanced the therapeutic efficacy and substantially inhibited 4T1 tumor growth. CMs obtained from surgically resected tumors were used to construct a personalized nanotherapeutic platform, which, in synergy with immune checkpoint blockade (ICB), effectively inhibited postsurgical tumor recurrence in 4T1 tumor. Our work offered a robust, safe strategy for cancer immunotherapy and prevention of postsurgical tumor recurrence.
- 6 October 2023
- Published by Elsevier in Chemical Engineering Journal
- Vol. 475
An ultrathin Zn-based layered double hydroxides augment degradation of mutant p53 to improve tumor therapy
- 6 October 2023
- Published by Elsevier in Chemical Engineering Journal
- Vol. 475
An ultrathin Zn-based layered double hydroxides augment degradation of mutant p53 to improve tumor therapy
- 1 April 2019
- Published by Elsevier in Dyes and Pigments
- Vol. 163, 102-110
Smart choice of carbon dots as a dual-mode onsite nanoplatform for the trace level detection of Cr2O72-
- 1 April 2019
- Published by Elsevier in Dyes and Pigments
- Vol. 163, 102-110
Smart choice of carbon dots as a dual-mode onsite nanoplatform for the trace level detection of Cr2O72-
- 1 January 2019
- Published by Elsevier in Journal of Alloys and Compounds
- Vol. 771, 418-423
An efficient route to assemble novel organometal halide perovskites and emission evolution performance
- 1 January 2019
- Published by Elsevier in Journal of Alloys and Compounds
- Vol. 771, 418-423
An efficient route to assemble novel organometal halide perovskites and emission evolution performance